Episode 271: ESMO 2023: THOR - Erdafitinib in Bladder Cancer

Yohann Loriot, MD, PhD, gives an update on the THOR randomized phase 3 trial on erdafitinib versus chemotherapy in patients with advanced or metastatic urothelial cancer.

Dr. Loriot is a physician scientist and medical oncologist at Gustave Roussy Cancer Institute and serves as director of the institute’s bladder cancer program.